Stock screenerAll disclosures →
EDGAR →
LBRX
Conviction 100HealthcareScan · Mon, Aug 10, 2026LBRX$45.79-4.61%
ResistanceSupportVol 14Vol MA14 515.06K
May 11May 28Jun 16Jul 6Jul 23Aug 10
Price45.79
Change-4.61%
Gap+0.10%
Rel volume2.48×
Avg volume412.13K
Avg $ vol16.41M
SMA 2037.97
SMA 5033.46
SMA 20025.68
Price vs 50+36.83%
Price vs 200+78.29%
MA stackbullish
50/200 cross—
Supertrendup · 39.72
RSI (14)72
MACD hist1.01
MACD cross—
Stoch %K / %D80 / 90
ADX (14)43
+DI / −DI32 / 12
RSI divergenceBearish
MACD divergenceBearish
ATR %+6.10%
ADR %7.46%
52w high48.18
52w low14.61
From 52w high-4.97%
Above 52w low+213.38%
New 52w highNo
SqueezeOff
Bollinger width62.13%
%B0.83
Donchian pos83.04%
Donchian high49.14
Donchian low29.36
AVWAP (52w high)46.49
vs AVWAP high-1.52%
AVWAP (52w low)26.32
vs AVWAP low+73.98%
OBV trendUp
Chaikin MF (20)0.23
Today vs 20d2.48×
Avg vol (14d)515.06K
Avg vol (20d)412.13K
Avg $ vol (20d)16.41M
Market cap1.31B
RS 3m (vs SPY)+44.40%
RS 6m (vs SPY)+87.06%
RS line new highNo
Trend template—
Technical rank95.2
1 week+6.87%
1 month+38.95%
3 months+43.21%
6 months+92.21%
1 year—
YTD+124.00%
P/E-52.09
P/B3.47
P/S—
P/FCF-37.24
EPS-3.13
Div yield—
ROE-6.66%
ROA-6.41%
Debt/Eq—
Current35.68
EV/EBITDA—
Gross margin—
Net margin—
Rev growth—
EPS growth60.06%
Price target47.43
Target upside3.59%
Analyst ratingBuy
Institutional104.55%
Ent. value992.28M
Revenue—
Net income-19.05M
Gross profit—
Free cash flow-35.26M
IndustryBiotechnology
ExchangeNasdaq
Shares out28.68M
Employees27
ListedThu, Sep 11, 2025
Free float23.84M
Float %83.2%
Short interest4.26M
Days to cover17.6d
Short volume35.2%
Squeeze score76 / 100
Next earnings—
EPS forecast—
Last EPS vs est−$0.67 vs −$0.75
Last surprise+10.7% beat
Setup gradeA+
Conviction100 / 100
Pattern quality—
Tech rank95.2 / 100
Group rank86 / 100 · Leading
Status laneNo active setup
Setup direction—
Pattern family
Resistance35.97
Support28.37
Days since event—
Candle confirm—
News sentiment—
Financials as of Tue, Mar 31, 2026 · quarterly.
Congress activity
Disclosed STOCK Act trades in LBRX
No recent disclosed trades by Congress in LBRX. STOCK Act filings can lag the trade by up to 45 days.
Insider activity
SEC Form 4 transactions in LBRX · 7 buys
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Garland J. Scott Director · Stock Option (Right to Buy) · 2026-06-03 | Grant | 10K | $0 | 2026-06-03 | 2026-06-05 |
RUFFOLO ROBERT R Director · Stock Option (Right to Buy) · 2026-06-03 | Grant | 10K | $0 | 2026-06-03 | 2026-06-05 |
Hemrajani Rekha Director · Stock Option (Right to Buy) · 2026-06-03 | Grant | 10K | $0 | 2026-06-03 | 2026-06-05 |
Nussbaum Ran Director · Stock Option (Right to Buy) · 2026-06-03 | Grant | 10K | $0 | 2026-06-03 | 2026-06-05 |
Kane William P Jr Director · Stock Option (Right to Buy) · 2026-06-03 | Grant | 10K | $0 | 2026-06-03 | 2026-06-05 |
Lenz Robert A. Director · Stock Option (Right to Buy) · 2026-06-03 | Grant | 12.5K | $0 | 2026-06-03 | 2026-06-05 |
Luse Rebecca Director · Stock Option (Right to Buy) · 2026-06-03 | Grant | 10K | $0 | 2026-06-03 | 2026-06-05 |
SEC filings
EDGAR filings in LBRX · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.
Start free — 14-day full access →Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.